AML cytogenetics: The complex just got simpler

Blood

Volumn 120, Issue 12, 2012, Pages 2357-2358

  Lazarus, Hillard M ^a   Litzow, Mark R ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHROMOSOME 17P; CHROMOSOME 5; CHROMOSOME 5P; CHROMOSOME ABERRATION; CYTOGENETICS; HUMAN; KARYOTYPING; NOTE; PRIORITY JOURNAL;

EID: 84866555935     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-448555     Document Type: Note

References (10)

1. Middeke JM, Beelen D, Stadler M, et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. Blood. 2012;120(12):2521-2528.
2. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
3. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
4. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116(13):2224-2228.
5. Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120(4):905-913.
6. Strickland SA, Sun Z, Ketterling RP, et al. Monosomal karyotype (MK) in older patients with acute myeloid leukemia (AML) on Eastern Cooperative Oncology Group Therapeutic trials: poor prognostic impact of MK, but not of monosomy 7 [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:256. Abstract 579.
7. Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008;26(35):5767-5774.
8. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009;115(9):1899-1905.
9. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-24988.
10. Pollock RM, Daigle SR, Olhava EJ, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:342. Abstract 780.